BOARD OBSERVER AGREEMENTBoard Observer Agreement • October 19th, 2018 • Aisling Capital IV, LP • Pharmaceutical preparations • Delaware
THIS BOARD OBSERVER AGREEMENT (this “Agreement”) is made as of October 17, 2018 (the “Effective Date”), between MARKER THERAPEUTICS, INC., a Delaware corporation formerly known as TapImmune Inc., a Nevada corporation (the “Company”), and AISLING CAPITAL IV, LP (the “Shareholder”). Unless otherwise specified herein, all of the capitalized terms used herein are defined in Section 3 hereof.
JOINT FILING AGREEMENTJoint Filing Agreement • October 19th, 2018 • Aisling Capital IV, LP • Pharmaceutical preparations
Each of the undersigned hereby acknowledges and agrees, in compliance with the provisions of Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, that the Schedule 13D to which this Agreement is attached as an Exhibit, and any amendments thereto, will be filed with the Securities and Exchange Commission jointly on behalf of the undersigned. This Agreement may be executed in one or more counterparts.
